Resultados de búsqueda

Unmasking snake venom of Bothrops leucurus: purification and pharmacological and structural characterization of new PLA2 Bleu TX-III. por Marangoni, Fábio André, Ponce-Soto, Luis Alberto, Marangoni, Sergio, Landucci, Elen Cristina Teizem

Ver este registro en EBSCOhost

Biochemical, pharmacological, and structural characterization of new basic PLA2 Bbil-TX from Bothriopsis bilineata snake venom. por Corasolla Carregari, Victor, Stuani Floriano, Rafael, Rodrigues-Simioni, Lea, Winck, Flavia V, Baldasso, Paulo Aparecido, Ponce-Soto, Luis Alberto, Marangoni, Sergio

Ver este registro en EBSCOhost

Can Institutional Reform Have a Lasting Impact on the Policy Agenda? Evidence From the 10-1 in Austin, TX. por Shannon, Brooke Nicole

Ver este registro en EBSCOhost

Has patient survival following renal transplantation improved in the era of modern immunosuppression? por Hernández, Domingo, Moreso, Francesc

Ver este registro en EBSCOhost

The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understan... por Hofman, Paul, Calin, George A., Mani, Sandurai A., Bontoux, Christophe, Ilié, Marius, Wistuba, Ignacio I.

Ver este registro en EBSCOhost

Are antipsychotics effective adjunctive Tx for patients with moderate-to-severe depression? por Bleacher, Heather, Koerperich, Lindsay, Malam, Naomi, DeSanto, Kristen

Ver este registro en EBSCOhost

Hypothermia in adults: A strategy for detection and Tx. por Pyzocha, Natasha J., Steele, Joseph L.

Ver este registro en EBSCOhost

The case for inpatient initiation of antiarrhythmic therapy...presented at 'Optimal Management of Atrial Fibrillation: a Case Study Approach' symposium, November 7, 1998, Dallas, T... por Myerburg RJ, Kloosterman M, Yamamura K, Mitrani R, Interian A Jr., Castellanos A

Ver este registro en EBSCOhost

The role of nonpharmacologic therapies for the treatment of atrial fibrillation...presented at 'Optimal Management of Atrial Fibrillation: a Case Study Approach' symposium, Novembe... por Guerra PG, Lesh MD

Ver este registro en EBSCOhost

Optimal management of the patient with chronic atrial fibrillation: whom to cardiovert?...presented at 'Optimal Management of Atrial Fibrillation: a Case Study Approach' symposium,... por Miller JM, Jayachandran JV, Coppess MA, Olgin JE

Ver este registro en EBSCOhost

Antithrombotic therapy in nonrheumatic/nonvalvular atrial fibrillation...presented at 'Optimal Management of Atrial Fibrillation: a Case Study Approach' symposium, November 7, 1998... por Gersh BJ

Ver este registro en EBSCOhost

Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist...presented at 'Optimal Management of Atrial Fibrillation:... por Thibault B, Nattel S

Ver este registro en EBSCOhost

Management of intermittent atrial fibrillation: drugs to maintain sinus rhythm...presented at 'Optimal Management of Atrial Fibrillation: a Case Study Approach' symposium, November... por Olgin JE, Viskin S

Ver este registro en EBSCOhost

Optimal management of the patient with an episode of atrial fibrillation in and out of the hospital: acute cardioversion or not?...presented at 'Optimal Management of Atrial Fibril... por Knight BP, Morady F

Ver este registro en EBSCOhost

Amarillo TX. por CAMPBELL, KRISTEN

Ver este registro en EBSCOhost

Socioeconomic disparities associated with awareness, access, and usage of Pre-Exposure Prophylaxis among Latino MSM ages 21–30 in San Antonio, TX. por Garcia, Moctezuma, Saw, Guan

Ver este registro en EBSCOhost

Registros en trasplante renal: ¿cómo optimizar su utilidad? por Hernández, Domingo, Sánchez, Emilio, Armas-Padrón, Ana María

Ver este registro en EBSCOhost

TRT may be viable Tx in men with PCa. por Gagnon L

Ver este registro en EBSCOhost

YIMBYISM, THE ENVIRONMENT, AND THE REMAKING OF RACE AND CLASS COALITIONS IN AUSTIN, TX. por Tretter, Eliot, Mueller, Elizabeth J., Heyman, Rich

Ver este registro en EBSCOhost

132TiP: Phase Ib open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line (1L) treatment (Tx) for metastatic HER2-overexpressing (HER2-OE) non... por Planchard, D., Yang, J.C-H., Nakajima, E., Schreffler, E., Chang, Y-T., Brahmer, J.R.

Ver este registro en EBSCOhost